The AKT genes and their roles in various disorders

American Journal of Medical Genetics, Part A

Volumn 161, Issue 12, 2013, Pages 2931-2937

  Cohen, M Michael ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

AKT1; AKT2; AKT3; Cellular functions of AKT effectors; G protein coupled receptor; MTORC2; Phosphatydlinositol 3 kinase and 3 kinase gamma; Phosphatydlinositol 4,5 bisphosphate and 3,4,5 trisphosphate; PTEN; RAS; Receptor tyrosine kinase

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; LIGAND; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN AKT1; PROTEIN AKT3; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ALEXANDER DISEASE; ARTICLE; CANCER GENETICS; CARCINOGENESIS; DIABETES MELLITUS; DIABETOGENESIS; DISEASE COURSE; ENZYME ACTIVITY; ENZYME REGULATION; FRONTAL CORTEX; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HEART DEVELOPMENT; HEART DISEASE; HEART FUNCTION; HEART PROTECTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEGANENCEPHALY SYNDROME; MICROCEPHALY; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONCOGENE; ONCOGENE AKT1; ONCOGENE AKT2; ONCOGENE AKT3; PATHOPHYSIOLOGY; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

AKT1; AKT2; AKT3; CELLULAR FUNCTIONS OF AKT EFFECTORS; G PROTEIN COUPLED RECEPTOR; MTORC2; PHOSPHATYDLINOSITOL 3 KINASE AND 3 KINASE GAMMA; PHOSPHATYDLINOSITOL 4,5 BISPHOSPHATE AND 3,4,5 TRISPHOSPHATE; PTEN; RAS; RECEPTOR TYROSINE KINASE;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; MICE; NEOPLASMS; NERVOUS SYSTEM DISEASES; ONCOGENE PROTEIN V-AKT; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84888029492     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.36101     Document Type: Article

References (40)

1. Ballif BC, Rosenfeld JA, Traylor R, Theise A, Bader PI, Ladda RL, Sell SL, Steinraths M, Surti U, McGuire M, Williams S, Farrell SA, Filiano J, Schnur RE, Coffey LB, Tervo RC, Stroud T, Marble M, Netzloff M, Hanson K, Aylsworth AS, Bamforth JC, Babu D, Niyazov DM, Ravnan JB, Schultz RA, Lamb AN, Torchia BS, Bejjani BA, Shaffer LG. 2012. High-Resolution array, CGH defines critical regions and candidate genes for microcephaly, abnormalities of the corpus callosum, and seizure phenotypes in patients with microdeletions of 1q43q44. Hum Genet 131:145-156.
2. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian Y-W, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patal K, Mousses S, Bittner M, Schevitz R, Lai M-HT, Blanchard KL, Thomas JE. 2007. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439-443.
3. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR. 1996. Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA Proc Natl Acad Sci 93:3636-3642.
4. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, Keastner KH, Bartolomei MS, Shulman GI, Birnbaum MJ. 2001. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBbeta). Science 292:1728-1731.
5. Cohen MM Jr Howell RE. 1999. Etiology of fibrous dysplasia and McCune-Albright syndrome. Int J Oral Maxillofac Surg 28:366-371.
6. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A, Shioi T, Irie-Sasaki JH. 2002. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110:737-749.
7. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJF, Gershenwald JE, Mills GB. 2008. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99:1265-1268.
8. Djordjevic S, Driscoll PC. 2002. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide-3-kinases. Trends Biochem Sci 27:426-432.
9. Emamian ES. 2012. AKT/GSK3 signaling pathway and schizophrenia. Front Mol Neurosci 5:1-12. Article 33.
10. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. 2004. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36:131-137.
11. Esfandiarei M, Luo H, Yanagawa B, Suarez A, Dabiri E, Si X, Rahmani M, McManus BM. 2004. Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent. J Virol 78:4289-4298.
12. Esfandiarei M, Suarez A, Amaral A, Si X, Rahmani M, Dedhar S, McManus BM. 2006. Novel role for integrin-linked kinase in modulation of coxsackievirus B3 replication and virus-induced cardiomyocyte injury. Circ Res 99:354-361.
13. Esfandiarei M, Boroomand S, Suarez A, Si X, Rahmani M, McManus BM. 2007. Coxsackievirus B3 activates nuclear kappa B transcription factor via a phosphatydlinositol-3 kinase/protein kinase B-dependent pathway to improve host cell viability. Cell Microbiol 9:2358-2371.
14. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MRPA. 2011. COSMIC: Mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res D945-D950.
15. George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC, Soos MA, Murgatroyd PR, Williams RM, Acerini CL, Dunger DBM, Barford D, Umpleby AM, Wareham NJ, Davies HA, Schafer AJ, Stoffel M, O'Rahilly S, Barroso I. 2004. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304:1325-1328.
16. Hers I, Vicent EE, Tavare JM. 2011. Akt signalling in health and disease. Cell Signal 23:1515-1527.
17. Hussain K, Challis B, Rocha N, Payne F, Minic M, Thompson A, Daly A, Scott C, Harris J, Smillie BJL, Savage DB, Ramaswami U, De Lonlay P, O'Rahilly S, Barroso I, Semple RK. 2011. An activating mutation of AKT2 and human hypoglycemia. Science 334:474.
18. Jackson SG, Al-Saigh S, Schultz C, Junop MS. 2011. Inositol pentakis phosphate isomers bind PH domains with varying specificity and inhibit phosphoinositide interactions. BMC Struct Biol 11:11.
19. Kohn AD, Summers SA, Birnbaum MJ, Roth RA. 1996. Expression of a constitutionally active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 271:31372-31378.
20. Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, Scott E, Bafna V, Hill KJ, Collazo A, Funari V, Russ C, Gabriel SB, Mathers GW, Gleeson JG. 2012. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway causes hemimegalencephaly. Nat Genet 44:941-945.
21. Lian L, Wang Y, Flick M, Choi J, Scott EW, Degen J, Lemmon MA, Abrams CS. 2009. Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis. Blood 113:3577-3584.
22. Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, Blumhorst C, Brockmann K, Calder P, Cherman N, Deardorff MA, Everman DB, Golas G, Greenstein RM, Kato BM, Keppler-Noreuil KM, Kuznetsov SA, Miyamoto RT, Newman K, Ng D, O'Brien K, Rothenberg S, Schwartzentruber DJ, Singhal V, Tirabosco R, Upton J, Weintroub S, Zackai EH, Hoag K, Whitewood-Neal T, Robey PG, Schwartzberg PL, Darling TN, Tosi LL, Mullikin JC, Biesecker LG. 2011. A mosaic activating mutation in AKT1 associated with Proteus syndrome. New Engl J Med 365:611-619.
23. Matsui T, Rosenzweig A. 2005. Convergent signal transduction pathways controlling cardiomyocyte survival and function: The role of PI3-kinase and Akt. J Mol Cell Cardiol 38:63-71.
24. Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, Force TL, Franke TF, Hajjar RJ, Rosenzweig A. 2001. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 104:330-335.
25. Matsui T, Nagoshi T, Rosenzweig A. 2003. Akt and PI3-kinase signaling in cardiomyoctye hypertrophy and survival. Cell Cycle 2:220-223.
26. Mizaa GM, Conway RL, Gripp KW, Lerman-Sagle T, Siegel DH, deVries LS, Lev D, Kramer N, Hopkins E, Graham JM Jr Dobyns WB. 2012. Megalencephaly-capillary malformation [MCAP] and megalencephaly-polydactyly-polymicrogyria-hydrocephalus [MPPH] syndromes: Two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis. Am J Med Genet Part A 158A:269-291.
27. Nakatani K, Sakaue H, Thompson DA, Weigel RJ, Roth RA. 1999. Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory serine phosphorylation site. Biochem Biophys Res Comm 257:906-910.
28. OMIM 164730 (AKT1), 164731 (AKT2), 611223 (AKT3), 610643 (PP2A), 609396 (PHLPP1), 601231 (mTOR), 612465 (TBC1D4), 116899 (CDKN1A), 600778 (CDKN1B), 603167 (BAD), 602233 (APAF1), 602448 (MAP3K5), 136533 (FOXO1), 123810 (CREB1), 606608 (YAP1), 164785 (MDM2), 609850 (TBC1D1), 163729 (NOS3).
29. Osaki M, Oshimura M, Ito H. 2004. PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis 9:667-676.
30. Oudit G, Kassiri Z, Zhou J, Liu QC, Liu PP, Backx PH, Dawood F, Crackower MA, Scholey JW, Penninger JM. 2008. Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress. Cardiovasc Res 78:505-514.
31. Parikh C, Janakiraman V, Wu WI, Foo CK, Kljavin NM, Chaudhuri S, Stawiski E, Lee B, Lin J, Li H, Lorenzo MN, Yuan W, Guillory J, Jackson M, Rondon J, Franke Y, Bowman KK, Sagolla M, Stinson J, Wu TD, Wu J, Stokoe D, Stern HM, Brandhuber BJ, Lin K, Skelton NJ, Seshagiri S. 2012. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancer. Proc Natl Acad Sci USA 109:19368-19373.
32. Poduri A, Evrony GD, Cai X, Elhosary PC, Beroukhim R, Lehtinen MK, Hills LB, Heinzen EL, Hill A, Hill RS, Barry BJ, Bourgeois BFD, Riviello JJ, Barkovich AJ, Black PM, Ligon KL, Walsh CA. 2012. Somatic activation of AKT3 cause hemispheric developmental brain malformations. Neuron 74:41-48.
33. Reddy KJ, Singh M, Bangit JR, Batsell RR. 2010. The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: An updated review. J Cardiovasc Med 11:633-647.
34. Rivière J-P, Mizaa GM, O'Roak BJ, Beddaoui M, Alcantara D, Conway RL, St-Onge J, Schwartzentruber JA, Gripp KW, Nikkel SM, Worthylake T, Sullivan CT, Ward TR, Butler HE, Kramer NA, Albrecht B, Armour CM, Armstrong L, Caluseriu O, Cytrnbaum C, Drolet BA, Innes AM, Lauzon JL, Lin AE, Mancini GMS, Meschino WS, Reggin JD, Sagger AK, Lerman-Sagie T, Uyanik G, Weksberg R, Zirn B, Beaulieu CL. Finding of Rare Disease Genes (FORCE) Canada, Majewski J, Buman DE, O'Driscoll M, Shendure J, Graham JM Jr Boycott KM, Dobyns WB, 2012. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nature Genet 44:934-940.
35. Roy HK, Olusola B, Clemens DL, Karolski WJ, Ratashak A, Lynch HT, Smyrk TC. 2002. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23:201-205.
36. Shiojima I, Walsh K. 2006. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev 20:3347-3365.
37. Staal SP. 1987. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary gastric adenocarcinoma. Proc Natl Acad Sci USA 84:5034-5037.
38. Stocker H, Hafen E. 2000. Genetic control of cell size. Curr Opin Genet Dev 10:529-535.
39. Tan K, Kimber WA, Luan J, Soos MA, Semple RK, Wareham NJ, O'Rahilly S, Barroso I. 2007. Analysis of genetic variation in Akt2/PKB-β in severe insulin resistance, lipodystrophy, type 2 diabetes, and related metabolic phenotypes. Diabetes 56:714-719.
40. Xu X, Sakon M, Nagano H, Yamamoto H, Hayashi N, Nakamori S, Umeshita K, Ito Y, Matsuura N, Mondon M. 2004. Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol Rep 11:25-32.